Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Aphexda Approved for Stem Cell Mobilization in Multiple Myeloma
Aphexda (motixafortide) is expected to be available later this month.
The Challenge of Making Cancer Trials More Diverse
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
Melflufen Demonstrates Efficacy in LIGHTHOUSE Trial; Drug’s Future Still Unclear
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
Oral Mezigdomide and Dexamethasone Proves Active in Rel/Ref Multiple Myeloma
The combination of oral mezigdomide and dexamethasone has shown activity in patients with relapsed/refractory multiple myeloma.
Some Immunosuppressed Patients Lack Anti-Spike Antibodies After Multiple COVID-19 Vaccinations
About 1 in 5 immunosuppressed individuals have no detectable IgG anti-spike antibodies after 3 or more COVID-19 vaccinations, a new study suggests.
Mask Mandates Have Kept One Cancer Center Free From COVID-19. Others Have Lifted Masking Requirements Despite Patient Concerns
Some cancer centers have lifted mask mandates that were intended to protect patients from COVID-19, despite patient concerns.
Cancer Survivors With Functional Disabilities Have Higher Health Care Costs
Cancer survivors with functional disabilities have higher health care usage and medical costs than survivors without disabilities, data suggest.
Lack of Representation in Studies May Impact MM Guidelines
Black patients are underrepresented in studies of multiple myeloma used to support IMWG guidelines, researchers found.
A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs
America’s pharmaceutical giants are suing this summer to block the federal government’s first effort at drug price regulation.
Deaths Among Cancer Patients Increased During the First 2 Years of the COVID-19 Pandemic
Deaths in patients with COVID-19 and cancer made up 81% of excess deaths among cancer patients during the first 2 years of the pandemic.
Systemic Therapies May Increase Risk of VTE in Patients With Cancer and COVID-19
Researchers found a higher risk of VTE in patients with cancer and COVID-19 who were receiving systemic cancer therapies.
Medicare Limits Cancer Patients’ Access to Home Infusions. A New Bill Could Change That.
The Preserving Patient Access to Home Infusion Act could make home infusions more accessible, particularly for patients with cancer.
US Cancer Death Rates on the Decline, but Urban/Rural Divide Persists
Cancer death rates have declined in the United States in recent years, but the declines are greater in urban than in rural areas, data suggest.
Industry-Sponsored Cancer Trials More Likely to Have Consent Documents Translated
Industry-sponsored cancer trials are more likely to have consent documents translated to languages other than English, a study suggests.
FDA Grants Accelerated Approval to Elrexfio for Relapsed/Refractory Multiple Myeloma
Elrexfio is expected to be available in the coming weeks.
Less Than Half of Cancer Trials Had Results Reported Within 1 Year of Completion
In an analysis of more than 10,000 cancer clinical trials, less than half had results reported within 1 year of trial completion.
Cancer Was Underdiagnosed in the First Year of the COVID-19 Pandemic
New research suggests that, in the United States, cancer was underdiagnosed during the first year of the COVID-19 pandemic.
Excessive Alcohol Consumption May Be Common in Cancer Patients, Survivors
Excessive alcohol consumption may be common among cancer survivors and cancer patients currently receiving treatment, a new study suggests.
With Twitter (Now X) in Flux, Is #MedTwitter Under Threat?
Oncology professionals share what #MedTwitter means to them and where they might go if Twitter (now X) becomes obsolete.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
Loading... 
Loading...